this demonstrated occlusion of the infarct-related coronary artery in 29 patients who were then randomized to treatment with intravenous apsac , 30 mg ( n = 16 ) , and placebo ( n = 13 ) 3.3 +/- 1.3 hours after the onset of symptoms .
C0027051
infarct
C0078956
apsac